Sitagliptin More Effectively Achieves A Composite Endpoint For A1c Reduction, Lack Of Hypoglycemia And No Body Weight Gain Compared With The Sulfonylurea Glipizide
Diabetes research and clinical practice(2010)
摘要
Sitagliptin and glipizide added to metformin provided similar degrees of glycemic efficacy in patients with type 2 diabetes with inadequate glycemic control on metformin monotherapy at 1 year; however, significantly more patients in the sitagliptin group achieved an A1C reduction of >0.5% without hypoglycemia and without an increase in body weight. (C) 2011 Elsevier Ireland Ltd. All rights reserved.
更多查看译文
关键词
Dipeptidyl peptidase-IV,Glipizide,Incretins,Sitagliptin,Sulfonylurea
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要